Healthcare Sector: New Analyst Stock Ratings and Share Price Targets

Wall St. Watchdog reveals information about companies for which stock analysts initiated coverage in the Healthcare sector for the week ending December 2nd, 2011.

  • Merck (NYSE:MRK): MKM Partners initiated coverage of this company with a rating of Buy and a price target of $38 on Nov 29th. The shares recently traded at $35.26, up $0.78, or 2.26% since the analyst’s rating. About the company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis. Get the most recent company news and stock data here >>
  • Emeritus Corp (NYSE:ESC): JMP Securities initiated coverage of this company with a rating of Mkt Outperform and a price target of $20 on Nov 29th. The shares recently traded at $16.38, up $1.62, or 10.98% since the analyst’s rating. About the company: Emeritus Corporation is a fully integrated senior housing services company focused on operating residential-style assisted-living communities. The Company develops and operates freestanding assisted living communities throughout the United States. Emeritus has also commenced development of its facilities in Japan and Canada. Get the most recent company news and stock data here >>
  • Genetic Technologies (NASDAQ:GENE): Ladenburg Thalmann initiated coverage of this company with a rating of Buy and a price target of $7.5 on Nov 30th. The shares recently traded at $3.90, up $0.03, or 0.78% since the analyst’s rating. About the company: Genetic Technologies Limited is a biotechnology company which does advanced DNA genetic research and testing. The Company has several gene-based patents which include intron sequence analysis, genomic mapping and fetal cell recovery. Genetic also operates a testing laboratory that performs disputed paternity testing by DNA techniques. Get the most recent company news and stock data here >>
  • Vical (NASDAQ:VICL): Global Hunter Securities initiated coverage of this company with a rating of Buy and a price target of $9 on Dec 1st. The shares recently traded at $4.63, up $0.04, or 0.87% since the analyst’s rating. About the company: Vical Incorporated develops gene-based pharmaceutical products for human therapy. The Company develops cancer product candidates, as well as develops vaccines for infectious diseases and gene-based delivery of therapeutic proteins for other disorders. Get the most recent company news and stock data here >>
  • Agenus (NASDAQ:AGEN): Global Hunter Securities initiated coverage of this company with a rating of Buy and a price target of $6 on Dec 1st. The shares recently traded at $2.45, down $0.03, or 1.21% since the analyst’s rating. About the company: Antigenics Inc. is a biotechnology company with immunotherapeutic vaccines in clinical trials in renal carcinoma, melanoma, and gastric and colorectal cancers. The Company’s vaccines are based on technology that uses heat shock proteins to modulate the immune system. Antigenics’ technology also has applications in infectious diseases and autoimmune disorders. Get the most recent company news and stock data here >>
  • Onyx Pharma (NASDAQ:ONXX): Rodman & Renshaw initiated coverage of this company with a rating of Mkt Outperform and a price target of $62 on Dec 1st. The shares recently traded at $44.00, down $0.26, or 0.59% since the analyst’s rating. About the company: Onyx Pharmaceuticals, Inc. discovers and develops novel therapeutics based upon the genetics of human disease, with an emphasis on cancer. The Company focuses on defining the function of certain mutated genes which are known to cause cancer, and on developing therapies to reverse the effects of the mutation or to kill the cancer cell. Get the most recent company news and stock data here >>
  • AdCare Health Systems (AMEX:ADK): Ladenburg Thalmann initiated coverage of this company with a rating of Buy and a price target of $7.5 on Dec 2nd. The shares recently traded at $3.95, up $0.1, or 2.6% since the analyst’s rating. About the company: ADCARE Health Systems, Inc. develops, owns, and manages retirement communities, assisted living facilities, nursing homes, and home health care services in the state of Ohio. The Company provides help with activities of daily living for seniors, senior housing, nursing homes, and consulting services. Get the most recent company news and stock data here >>
  • Anthera Pharma (NASDAQ:ANTH): Collins Stewart initiated coverage of this company with a rating of Buy and a price target of $13 on Dec 2nd. The shares recently traded at $6.56, up $0.08, or 1.23% since the analyst’s rating. About the company: Anthera Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing anti-inflammatory therapeutics for cardiovascular diseases, lupus and other serious diseases. Get the most recent company news and stock data here >>

(Note: Selected financial data are sourced from Briefing.com via the Wall St. Journal. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>